Evotec (NASDAQ:EVO) Sets New 52-Week Low - Should You Sell?

Key Points

• Evotec shares fell to a new 52-week low of $1.89, below both the 50-day moving average of $2.30 and the 200-day moving average of $2.74.
• Analyst sentiment has weakened, with recent downgrades to “hold” or “sell” and HC Wainwright cutting its price target to $4.00. The overall consensus remains “Hold,” with an average target of $3.00.
• Institutional ownership is limited at 5.81%, although several funds recently initiated or increased positions in the biotechnology company.

Evotec AG (NASDAQ:EVO - Get Free Report)'s stock price reached a new 52-week low during trading on Monday . The stock traded as low as $1.89 and last traded at $1.89, with a volume of 12713 shares changing hands. The stock had previously closed at $1.93.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on EVO shares. HC Wainwright decreased their target price on shares of Evotec from $7.00 to $4.00 and set a "buy" rating on the stock in a report on Wednesday, July 15th. Wall Street Zen cut Evotec from a "hold" rating to a "sell" rating in a report on Saturday, May 9th. Weiss Ratings reissued a "sell (d-)" rating on shares of Evotec in a research report on Tuesday, July 21st. Berenberg Bank lowered shares of Evotec from a "buy" rating to a "hold" rating in a report on Thursday, July 16th. Finally, TD Cowen cut shares of Evotec from a "buy" rating to a "hold" rating and set a $2.00 target price on the stock. in a research report on Wednesday, July 15th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Evotec presently has a consensus rating of "Hold" and an average price target of $3.00.

Evotec Trading Down 2.1%

The stock's fifty day moving average price is $2.30 and its two-hundred day moving average price is $2.74. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.33 and a quick ratio of 2.21.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Apollon Wealth Management LLC acquired a new stake in shares of Evotec in the 1st quarter worth $28,000. BNP Paribas Financial Markets increased its stake in shares of Evotec by 62.2% during the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company's stock worth $50,000 after acquiring an additional 4,600 shares during the period. Bank of America Corp DE raised its holdings in Evotec by 262.5% during the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after purchasing an additional 9,289 shares in the last quarter. Marshall Wace LLP purchased a new position in Evotec during the fourth quarter worth about $40,000. Finally, XTX Topco Ltd acquired a new stake in Evotec in the second quarter valued at about $66,000. 5.81% of the stock is currently owned by institutional investors and hedge funds.

About Evotec

Evotec SE NASDAQ: EVO is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec's service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source